2. Academic Validation
  3. A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination

A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination

  • Nat Nanotechnol. 2022 Sep;17(9):993-1003. doi: 10.1038/s41565-022-01177-2.
Guofang Zhang  # 1,  Yalin Cong  # 2 3 4,  Feng-Liang Liu  # 5,  Jiufeng Sun  # 6,  Jiantian Zhang 7,  Guoli Cao 1 8 9,  Lingqiang Zhou 10,  Wenjie Yang 1 8,  Qingle Song 1 8,  Fangjun Wang 10,  Ke Liu 1,  Jing Qu 1,  Jing Wang 3,  Min He 10,  Shun Feng 10,  Didar Baimanov 2 4 11,  Wei Xu 2 4 11,  Rong-Hua Luo 5,  Xin-Yan Long 5,  Shumin Liao 12,  Yunping Fan 12,  Yu-Feng Li 2 4 11,  Bai Li 2 11,  Ximing Shao 1,  Guocheng Wang 1,  Lijing Fang 1,  Huaiyu Wang 1,  Xue-Feng Yu 1,  Yan-Zhong Chang 9,  Yuliang Zhao 2 4 13 14,  Liang Li 1,  Peng Yu 7,  Yong-Tang Zheng 15,  Diana Boraschi 1 8 16,  Hongchang Li 17,  Chunying Chen 18 19 20 21,  Liming Wang 22 23 24 25,  Yang Li 26 27
Affiliations

Affiliations

  • 1 Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • 2 CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, Institute of High Energy Physics and National Center for Nanoscience and Technology of China, Chinese Academy of Sciences, Beijing, China.
  • 3 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  • 4 University of the Chinese Academy of Science, Beijing, China.
  • 5 Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
  • 6 Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.
  • 7 State Key Laboratory of Optoelectronic Materials and Technologies, Guangzhou Key Laboratory of Flexible Electronic Materials and Wearable Devices, Nanotechnology Research Center, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou, China.
  • 8 Laboratory of Immunology and Nanomedicine, and China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • 9 Laboratory of Molecular Iron Metabolism, College of Life Science, Hebei Normal University, Shijiazhuang, China.
  • 10 CAS Key Laboratory of Separation Sciences for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
  • 11 CAS-HKU Joint Laboratory of Metallomics on Health and Environment, and National Consortium for Excellence in Metallomics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
  • 12 Department of Otolaryngology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
  • 13 The GBA National Institute for Nanotechnology Innovation, Guangzhou, China.
  • 14 Research Unit of Nanoscience and Technology, Chinese Academy of Medical Sciences, Beijing, China.
  • 15 Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China. zhengyt@mail.kiz.ac.cn.
  • 16 Institute of Biochemistry and Cell Biology, National Research Council, Napoli, Italy.
  • 17 Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. hc.li@siat.ac.cn.
  • 18 CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, Institute of High Energy Physics and National Center for Nanoscience and Technology of China, Chinese Academy of Sciences, Beijing, China. chenchy@nanoctr.cn.
  • 19 University of the Chinese Academy of Science, Beijing, China. chenchy@nanoctr.cn.
  • 20 The GBA National Institute for Nanotechnology Innovation, Guangzhou, China. chenchy@nanoctr.cn.
  • 21 Research Unit of Nanoscience and Technology, Chinese Academy of Medical Sciences, Beijing, China. chenchy@nanoctr.cn.
  • 22 CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, Institute of High Energy Physics and National Center for Nanoscience and Technology of China, Chinese Academy of Sciences, Beijing, China. wangliming@ihep.ac.cn.
  • 23 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China. wangliming@ihep.ac.cn.
  • 24 University of the Chinese Academy of Science, Beijing, China. wangliming@ihep.ac.cn.
  • 25 CAS-HKU Joint Laboratory of Metallomics on Health and Environment, and National Consortium for Excellence in Metallomics, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China. wangliming@ihep.ac.cn.
  • 26 Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. yang.li@siat.ac.cn.
  • 27 Laboratory of Immunology and Nanomedicine, and China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. yang.li@siat.ac.cn.
  • # Contributed equally.
PMID: 35995853 DOI: 10.1038/s41565-022-01177-2
Abstract

The global emergency caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic can only be solved with effective and widespread preventive and therapeutic strategies, and both are still insufficient. Here, we describe an ultrathin two-dimensional CuInP2S6 (CIPS) nanosheet as a new agent against SARS-CoV-2 Infection. CIPS exhibits an extremely high and selective binding capacity (dissociation constant (KD) < 1 pM) for the receptor binding domain of the spike protein of wild-type SARS-CoV-2 and its variants of concern, including Delta and Omicron, inhibiting virus entry and Infection in angiotensin converting Enzyme 2 (ACE2)-bearing cells, human airway epithelial organoids and human ACE2-transgenic mice. On association with CIPS, the virus is quickly phagocytosed and eliminated by macrophages, suggesting that CIPS could be successfully used to capture and facilitate virus elimination by the host. Thus, we propose CIPS as a promising nanodrug for future safe and effective anti-SARS-CoV-2 therapy, and as a decontamination agent and surface-coating material to reduce SARS-CoV-2 infectivity.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z